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patients. ConClusions: This BIA will be essential to support CONITEC’s decision 
about insulin analogues for T1DM patients in Brazil. Treatment costs still impressive, 
considering that analogues’ values reach 10 times the unit values of human insulins, 
fact that did not happen in other countries where they are already covered.
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objeCtives: The budget impact model (BIM) is recognized as a useful tool to help 
payers assess the economic value of new medicines approved for use. Although 
they are not considered as robust as cost effectiveness models, they do allow for 
short-term estimates of pharmacy impact and potential costs/offsets with the 
inclusion of the new medicine on formulary. Evolving IT platforms, such as the 
iPad, are offering new opportunities, but also changing end user expectations for 
these models. Albiglutide is an investigational, once weekly, Glucagon-Like Peptide-1 
Receptor Agonist (GLP-1RA) for the treatment of Type 2 Diabetes (T2D). We describe 
the development of an iPad application (app) derived from an excel-based BIM 
for use with US payer customers to inform access and reimbursement decisions 
for albiglutide. Methods: An excel-based BIM estimating the 1-5 year impact 
of including albiglutide on formulary compared to other available GLP-1RA’s was 
developed as per guidance from AMCP and following ISPOR good research prac-
tices. Given the increased use and demand for apps, we transformed the excel 
model into an app that would allow for modeling simulations to be run on an iPad 
adhering to these good practice guidelines. Results: The excel model was built 
according to the good practice guidelines and demonstrated the budget impact of 
introducing albiglutide for the treatment of T2D. The BIM was designed in a way 
to allow for successful conversion into a standalone app that utilized an improved 
user interface for interactive discussions around the value of albiglutide with US 
payers. ConClusions: The app version of the albiglutide BIM is a useful, comple-
mentary tool to the excel-based BIM. The app maintains its functionality according 
to ISPOR and AMCP recommendations.
PDB34
somaTroPin Dose analysis for TreaTmenT of hyPoPiTuiTarism in 
PuBlic Brazilian healTh sysTem (sus)
Ferreira C.N., Rufino C.S., Manfrin D.F.
Pfizer, Inc., São Paulo, Brazil
objeCtives: This analysis aims to determine, in International Units (IU), the soma-
tropin volume waste of presentations with 4 IU and 12 IU compared to 16 IU and 
36 IU, when used for treatment of Turner Syndrome and for children treatment 
with disorders of growth due to deficiencies of growth hormone. Methods: The 
amount waste per month was analyzed, in IU, from the dosage indicated in the 
Project of Clinical Protocol Guideline (PCDT) for Hypopituitarism of the Brazilian 
Health Ministry and a comparative analysis was done between presentations of 
4 IU/ 12 IU (approved by Ministry) and of 16 IU/ 36 IU. Results: The average loss 
per treatment/month (Turner Syndrome and children with growth disorders) are 
18,36 IU, 12,08 IU, 0,38 IU and 2,01 IU presentations with 4IU,12IU, 16IU and 36IU 
respectively. ConClusions: Therefore, if the SUS adopt presentations of 16IU or 
36IU, that could be reduce the losses in an average of 97,5% and 87% respectively in 
month/patient, minimize the treatment cost, optimize doses number and achieve 
more patients. Moreover, it is more advantageous because they take up less space 
for storage and for transportation.
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objeCtives: To estimate the impact of the cost of diabetes mellitus (DM) in 
Brazil based on the ratio (“R”) of health care expenses of households with at least 
one person using medication for diabetes to those without diabetes medication 
use. Methods: We utilized data from the Family Budget Study (POF – Pesquisa de 
Orçamentos Familiares), a representative sample of 59.548 households investigated 
in 2008-2009 by the Brazilian Institute of Geography and Statistics (IBGE). The data 
were analyzed using Microsoft Excel and R (version 3.0.2). Households were catego-
rized based on the purchase (or no cost receipt) of diabetes medications by fam-
ily members. Expenses included those for hospitalization, medical consultations, 
health insurance, drugs and medical supplies. Analyses were conducted for Brazil, 
for regions and for those with and without health insurance coverage. Results are 
weighted so as to represent the Brazilian population. Results: Households with 
diabetes (6.2% of the total) more frequently (26.3% vs. 8.5%) had members > 60 years 
of age. Expenses increased with increasing household income. Overall, for Brazil, 
the ratio “R”, adjusted through regression analyses for the age and sex distribution 
of the family members, household income and regional location, was 1.81 (95%CI 
1.69-1.95), indicating that expenses were 81% greater in households where diabetes 
was present than in those without. The expenses with the purchase of medicines to 
treat DM increase with increasing income. ConClusions: Health care expenses 
are notably greater in Brazilian households having family members with diabetes.
PDB36
DieT moDificaTion in PaTienTs wiTh DiaBeTes anD iTs associaTion 
wiTh heaTh care uTilizaTion anD exPenDiTure
Alfaifi A.1, Althemery A.U.1, Lai L.2
1Nova Southeastern University, Plantation, FL, USA, 2Nova Southeastern University,  
Ft. Lauderdale, FL, USA
PDB30
saxagliPTin/meTformin exTenDeD-release (xr) for The TyPe 2 DiaBeTes 
(T2Dm) TreaTmenT in venezuela: a BuDgeT imPacT analysis
Elgart J.F.1, Gonzalez L.2, Perez Monteverde A.3, Garrido Lecca S.4, Aiello E.5, Gagliardino J.J.2
1CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro 
Colaborador OPS/OMS), La Plata, Buenos Aires, Argentina, 2CENEXA - Centro de Endocrinología 
Experimental y Aplicada (UNLP-CONICET La Plata, Centro Colaborador OPS/OMS), Buenos 
Aires, Argentina, 3Centro Médico Docente la Trinidad, Caracas, Venezuela, 4Bristol-Myers Squibb 
Company, Lima, Peru, 5Bristol-Myers Squibb Company, Buenos Aires, Argentina
objeCtives: To estimate the budget impact of the use of saxagliptin/metformin 
XR fixed-dose combination compared to the current treatment of people with 
T2DM, in Venezuela. Methods: We used an MS Excel-based budget impact model 
assuming coverage of one million people in the health care system of Venezuela, 
with a 3-year time horizon. DM prevalence was obtained from published literature. 
Pharmaceutical expenses of oral antidiabetic agents (OADs) were analyzed exclud-
ing other medical costs. The cost of OADs was based upon list prices, expressed 
in Venezuelan Bolivars (VEF$) 2013 (exchange rate: 1 US-dollar = 6.30 VEF$). The 
market share of the different drugs was based upon QUALIDIAB Database, market 
studies and data provided by Bristol-Myers Squibb. A progressive increase of mar-
ket share was assumed for saxagliptin/metformin XR among all the OADs; 1.14%, 
2.65% and 3.0% for the 1st, 2nd and 3rd year, respectively. The budget impact is 
reported in terms of annual budget impact, per member per-month (PMPM) and 
per patient per month (PPPM). A Monte Carlo simulation (10,000 iterations) was 
done as part of the sensitivity analysis. Results: the net budget impact estimated 
for the introduction of saxagliptin/metformin XR combined was VEF$503,807 for 
the first year, VEF$1,183,333 for the second year and VEF$1,353,554 for the third 
year; the cumulative net budget impact was VEF$3,040,703. PMPM was VEF$0.04, 
VEF$0.10 and VEF$0.11 for the first, second and third year respectively. PPPM was 
VEF$1.67, VEF$4.0 and VEF$4.65 each year, respectively. The cumulative impact in 
the total annual budget for oral antidiabetic agents represented an increase of 2.36%. 
Monte Carlo simulation showed that cumulative budget impact varied from 1.32 to 
8.74%. ConClusions: incorporation of saxagliptin/metformin XR combination into 
the health care system of Venezuela, as a treatment option for people with T2DM, 
would have a minimal budgetary impact.
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objeCtives: CANA, an SGLT2 inhibitor, is a recently approved oral antihyperglyce-
mic agent (AHA) for the treatment of adults with T2DM. As the prevalence and cost 
of T2DM continue to rise, payers seek treatment options to improve care and reduce 
cost. Budget impact analysis may help payers in the formulary decision-making 
process. To estimate the three-year budget impact of adding CANA to a hypothetical 
health plan formulary in place of other branded AHAs. Methods: The model was 
developed from the perspective of a US health plan with 1 million members. The 
prevalence of people diagnosed and treated with T2DM is based on US epidemiol-
ogy statistics. Drug costs were estimated using August 2013 wholesale acquisition 
costs. Publically available estimates of 2012 market shares of the branded AHAs and 
estimated 2013, 2014, and 2015 market shares of CANA for Years 1-3 (Year 1: 0.3%, 
Year 2: 1.8%, Year 3: 2.1%) were used. The base case analysis examined an increasing 
CANA market share with a proportional decrease in the market share of the other 
branded drugs. Results are presented as the difference in pharmacy budget, overall 
and per-member per-month (PMPM). Results: Prior to the introduction of CANA, 
the estimated pharmacy budget for branded non-insulin AHAs in this hypothetical 
plan was almost $48 MM/year. With CANA added to the formulary, the budget is 
forecasted to decrease by $71,902 at Year 1, $431,409 at Year 2, and $503,311 at Year 
3. The PMPM expenditures decrease from $4.00 when CANA was unavailable to $3.95 
at Year 3 of CANA uptake. ConClusions: The results show the positive budget 
impact of adding CANA to the formulary. As payers continually face rising health 
care costs, an AHA that can safely and effectively treat T2DM and lower pharmacy 
costs would be considered highly valuable.
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objeCtives: Type 1 Diabetes Mellitus (T1DM) is an endocrine autoimmune disease 
with onset usually in childhood and which, being chronic, affects people of working 
age. It affects approximately 0.3% of the population and has high personal and social 
impact. The National Committee for Incorporation of Technologies in Health System 
(CONITEC) is responsible for recommending the inclusion or not of technologies in 
Brazilian public health system and has drawn up a budget impact analysis (BIA) of 
insulin analogues for the treatment of T1DM for help the decision making. Methods: 
A BIA of insulin analogues in SUS compared to human insulin (NPH and Regular) 
was performed. The analysis’ time horizon was 5 years, using a diabetes prevalence 
of 7.6% and 5% of T1DM between them (602,742), considering an annual growth rate 
of 0.8143% and a market share of 20%, 30%, 40%, 50% and 100%. The mean total 
insulin dose considered was 0.75IU/kg/day, with an average personal weight of 70kg, 
which means 52.5IU/day, 50% of each insulin type (basal and rapid). Unit purchase 
prices of insulins were obtained in the health system prices database and calcu-
lated the weighted average. For human insulins, were considered the values of last 
purchase of the Ministry of Health. Results: The budget impact of basal analogues 
would be R$202.8 million in the 1st year, considering 20% of target population, reach-
ing approximately R$1 billion in 100% of patients. For rapid analogues, the budget 
impact would be R$62.9 million in the 1st year, reaching R$324.9 million in 100% of 
